CXCL9 and metabolic dysfunction-associated steatohepatitis: Moreover, high levels of MIG/CXCL9 are found in the livers of patients with NASH, which suggests that the MIG/CXCL9-CXCR3 axis is a potential target for the treatment of liver fibrosis in both humans and animals [54].